Long-term follow-up of 500 patients with mild to moderate hypertension who had successfully completed a 3-month general practice study of a timolol-bendrofluazide combination ('Prestim').

Abstract

A sample of 500 patients with mild to moderate hypertension, who had been successfully controlled on once daily timolol/bendrofluazide at the end of a 3-month general practice study, was followed up after approximately 1 year of treatment. Physicians who had participated in the trial were questioned on the current status of these patients. Out of 479 reports received, data showed that 358 (75%) patients were still normotensive 47 weeks after starting treatment with timolol/bendrofluazide and in a further 8 patients other antihypertensive agents had been added to this therapy. Of the 113 patients no longer receiving timolol/bendrofluazide, only 38 (7.9%) had stopped therapy due to adverse effects. It is concluded that the results are a further indication that timolol/bendrofluazide offers an acceptable and balanced long-term form of therapy in hypertension for both the patient and the physician.

• Authors: A C Head, B T Marsh, I T Fairey
• Journal: Current medical research and opinion (Curr Med Res Opin) Vol. 10 Issue 8 Pg. 562-5 ( 1987) ISSN: 0300-7995 [Print] England
• PMID: 3315469 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Drug Combinations
• Bendroflumethiazide
• prestim
• Timolol

Topics

• Adult
• Aged
• Bendroflumethiazide (adverse effects, therapeutic use)
• Body Weight (drug effects)
• Clinical Trials as Topic
• Drug Combinations (adverse effects, therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Hypertension (drug therapy)
• Male
• Middle Aged
• Pulse (drug effects)
• Timolol (adverse effects, therapeutic use)